Metodološka beleška. Methodological Note. - Merck d.o.o. Srbija - - Merck d.o.o. Serbia - 1. Uvod. 1. Introduction. 2. Definicije. 2.
|
|
- Tracy Randall
- 6 years ago
- Views:
Transcription
1 Methodological Note - Merck d.o.o. Serbia - 1. Introduction This Methodology note summarizes the methodologies used in preparing Merck s disclosure according to the EFPIA HCP/HCP Disclosure Code and identifying transfers of value, made directly or indirectly to or for the benefit of a Recipient. Metodološka beleška - Merck d.o.o. Srbija - 1. Uvod Ova Metodološka beleška rezimira metodologije korišćene u pripremi objava kompanije Merck saglasno Kodeksu federacije EFPIA o objavljivanju podataka (Kodeks o objavi prenosa vrednosti od farmaceutskih kompanija zdravstvenim radnicima i zdravstvenim ustanovama), kao i u identifikovanju prenosa vrednosti izvršenih neposredno ili posredno Primaocu, ili u njegovu korist. 2. Definitions Recipients Any HCP or HCO, whose primary practice, principal professional address or place of incorporation is in Europe 1. HCO Any legal person (i) that is a healthcare, medical or scientific association or organization (irrespective of the legal or organizational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society (except for patient organizations within the scope of the 2. Definicije Primaoci Svaki ZR (zdravstveni radnik) ili ZO (zdravstvena ustanova), čija je primarna praksa, glavna poslovna adresa ili mesto osnivanja, u Evropi 2. ZO Svako pravno lice (i) koje je zdravstvena, medicinska ili naučna asocijacija ili organizacija (nezavisno od pravnog oblika organizovanja) kao što je bolnica, klinika, ambulanta, univerzitet ili druga nastavna ustanova ili učeno društvo (osim organizacija pacijenata u okviru EFPIA Kodeksa za OP) čija se 1 As defined in the EFPIA HCP/HCO Disclosure Code: Those countries currently include the following 33 countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine and the United Kingdom. 2 Kao što je definisano u Kodeksu o objavi EFPIA: Ove zemlje trenutno obuhvataju sledeće 33 zemlje: Austrija, Belgija, Bugarska, Hrvatska, Kipar, Republika Češka, Danska, Estonija, Finska, Francuska, Nemačka, Grčka, Mađarska, Irska, Italija, Letonija, Litvanija, Malta, Holandija, Norveška, Poljska, Portugal, Rumunija, Rusija, Srbija, Slovačka, Slovenija, Španija, Švedska, Švajcarska, Turska, Ukrajina i Velika Britanija.
2 EFPIA PO Code) whose business address, place of incorporation or primary place of operation is in Europe or (ii) through which one or more HCPs provide services. poslovna adresa, mesto osnivanja ili osnovno mesto na kome obavlja delatnost nalaze u Evropi ili (ii) koje pruža usluge preko jedne ili više ZO. HCP Any natural person that is a member of the medical, dental, pharmacy or nursing professions or any other person who, in the course of his or her professional activities, may prescribe, purchase, supply, recommend or administer a medicinal product and whose primary practice, principal professional address or place of incorporation is in Europe. For the avoidance of doubt, the definition of HCP includes: (i) any official or employee of a government agency or other organization (whether in the public or private sector) that may prescribe, purchase, supply or administer medicinal products and (ii) any employee of a Member Company whose primary occupation is that of a practicing HCP, but excludes (x) all other employees of a Member Company and (y) a wholesaler or distributor of medicinal products. Kind of ToVs Direct and indirect transfers of value, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development and sale of prescription-only Medicinal Products exclusively for human use. ZR Svako fizičko lice koje pripada profesiji lekara, stomatologa, farmaceuta ili medicinske sestre/tehničara ili svako lice koje tokom svojih radnih aktivnosti može da prepisuje, kupuje, snabdeva, preporučuje ili primenjuje lekove i čija je osnovna delatnost, glavna radna adresa ili mesno osnivanja u Evropi. Da se izbegne svaka sumnja, ova definicija ZR uključuje: (i) svakog funkcionera ili zaposlenog u državnoj agenciji ili drugoj organizaciji (bilo u javnom ili privatnom sektoru) koji može da prepisuje, kupuje, snabdeva ili primenjuje lekove, i (ii) svakog zaposlenog u Kompaniji članici čije je osnovno zanimanje da bude ZR u praksi, ali isključuje (x) sve druge zaposlene u Kompaniji članici i (y) veleprodaju i distributere lekova. Vrste prenosa vrednosti Neposredni ili posredni prenos vrednosti, bilo u gotovini ili u robi, ili na drugi način, bilo za promotivne ili neke druge svrhe, u vezi sa razvojem i prodajom lekova koji se izdaju na recept isključivo za upotrebu u humanoj medicini. - Direct ToVs Transfers of value made directly by Merck for the benefit of a Recipient. - Neposredni prenosi vrednosti Neposredni prenosi vrednosti su oni koji obavi direktno Merck u korist Primaoca.
3 - Indirect ToVs Transfers of value made on behalf of Merck for the benefit of a Recipient, or transfers of value made through an intermediate and where the Merck knows or can identify the HCP/HCO that will benefit from the Transfer of Value. - Aggregate ToVs For Transfers of Values, which cannot be disclosed on an individual basis for legal reasons, the amounts attributable to such ToVs will be disclosed on an aggregate basis. The aggregate disclosure identifies (i) the number of Recipients covered by such disclosure, and (ii) the aggregate amount attributable to Transfers of Value to such Recipients. - Research and Development Transfers of Value Transfers of Value to HCPs or HCOs related to the planning or conduct of (i) non-clinical studies (as defined in OECD Principles on Good Laboratory Practice); (ii) clinical trials (as defined in Directive 2001/20/EC); (iii) Independent Investigator Trials and Investigator Sponsored Trials (iv) non-interventional studies that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of, HCPs specifically for the study (Section of the HCP Code). 3. Disclosure s scope Products concerned Prescription-only medicine. Exception: In addition to disclosing ToV s concerning prescription-only medicine, some countries are bound - Posredni prenosi vrednosti Posredni prenosi vrednosti su oni koji se obave u ime kompanije Merck u korist Primaoca, ili prenosi vrednosti koji se obave preko posrednika, i gde Merck zna ili može da identifikuje ZR/ZO koji će imati koristi od takvog Prenosa vrednosti. - Zbirni prenosi vrednosti Za prenose vrednosti koje se ne mogu objaviti na pojedinačnoj osnovi iz pravnih razloga, iznosi koji se odnose na ove prenose vrednosti će biti objavljene zbirno. Objavljivanje zbirnog prenosa vrednosti otkriva (i) broj Primalaca koje takva objava pokriva, i (ii) zbirni iznos koji se odnosi na prenose vrednosti ovakvim Primaocima. - Prenos vrednosti za istraživanje i razvoj Prenos vrednosti na ZR ili ZO povezan sa planiranjem ili sprovođenjem (i) nekliničkih ispitivanja (kako je to definisano u Principima dobre laboratorijske prakse OECD); (ii) kliničkih ispitivanja (kako je to definisano u Direktivi 2001/20/EC); (iii) Nezavisne istraživačke studije i klinička ispitivanja koje sponzoriše istraživač (iv) neintervencijskih studija koje su prospektivne prirode i koje uključuju prikupljanje podataka od pojedinačnih ZR ili u njihovo ime ili u ime grupa ZR, konkretno za datu studiju (član 15.1 Kodeksa o ZR). 3. Obim objavljivanja Proizvodi na koje se odnosi Lekovi koji se izdaju samo na recept. Izuzetak: Pored objavljivanja prenosa vrednosti koje se odnose na lekove koji se izdaju na recept, neke zemlje
4 by legislation or local Pharma Association provisions to disclose their OTC interactions as well. njihovo zakonodavstvo, ili propisi njihovih farmaceutskih udruženja obavezuju da objavljuju i svoje interakcije koje se odnose i na lekove koji se izdaju bez recepta. Excluded transfers of value a. solely related to over-the-counter medicines (except in some countries in which over-the-counter-medicines are required to be included in the disclosure); b. provision of materials and objects of informative or educational character; c. meals (except in some countries in which meals are required to be included in the disclosure); d. samples; e. fees charged by logistics agencies assisting in organising travels and meetings; f. discounts, price reductions and other trading devices commonly used in the sale of medicinal products; g. healthcare packages provided by private entities purchased by Signatories for their employees; h. related to anonymous marketing research. Isključeni prenosi vrednosti a. Koji se isključivo odnose na lekove koji se izdaju bez recepta (osim u nekim zemljama u kojima se i lekovi koji se izdaju bez recepta moraju uključiti u objavu); b. Davanje materijala i predmeta informativnog ili obrazovnog karaktera; c. Obroci (osim u nekim zemljama u kojima se i obroci moraju uključiti u objavu); d. uzorci; e. honorari koje naplaćuju logističke agencije koje pomažu u organizaciji putovanja i sastanaka; f. popusti, sniženje cena i druga trgovačka sredstva koja se često koriste u prodaji medicinskih proizvoda; g. paketi zdravstvenog osiguranja koje nude privatne organizacije, a koje Potpisnici kupuju za svoje zaposlene; h. koje se odnose na anonimna ispitivanja tržišta. Transfer of value date a. Date of Transfer of Value is the date of the effective payment to the recipient. b. If the payment is executed at several different dates (e.g. for one and the same assignment fees are payed at another date than travel costs) the date of the largest amount of payment effected is taken as payment date. c. In case of sponsorship of HCP/HCO to attend medical/scientific meetings/events managed by third party incl. payment by third party the event date is taken as transfer Datum prenosa vrednosti a. Datum prenosa vrednosti je datum izvršene isplate primaocu. b. Ukoliko se plaćanje vrši u nekoliko različitih datuma (npr. za jedan isti angažman, honorar se plaća jednog dana a putni troškovi se plaćaju drugog dana) za datum prenosa vrednosti se uzima datum kada je izvršena najveća uplata. c. U slučaju sponzorisanja učešća ZR/ZO na medicinskom/naučnom događaju koji organizuje treća strana, uklj. i plaćanje treće strane, datum događaja se uzima kao datum prenosa vrednosti ukoliko se dan
5 of value date if the effective payment date of registration fees to event organizer, accommodation costs to hotels etc. significantly differ from the transfer of value date (= receipt of the congress batch, date of accommodation etc.) of the recipient. Direct transfer of value a. Transfers of value are represented as the cost amount for Merck and not the recipient s revenue. b. Non-financial transfers of value are disclosed based on the financial valuation of the nonfinancial spend (goods / service time spend etc.). Indirect transfer of value a. Transfers of value provided to HCOs by a third party company, e.g. through an organizer of medical events are reported with the HCO as recipient. b. Transfers of value to individual HCPs executed by a third party company are reported with the individual HCP as recipient. c. Transfers of value to individual HCPs (e.g. invitations, covering travel or accommodation costs) executed by a HCO are reported as transfer of value to the HCO. Transfer of value in case of partial attendances or cancellation a. In case of partial attendance or cancellation, or services not delivered, but value was transferred anyway e.g. according to contract clause, the transferred value is disclosed. b. If no value was transferred, the information on the transfer of value is not part of disclosure. uplate kotizacije organizatoru događaja, troškova smeštaja hotelima, itd. znatno razlikuju od datuma prenosa vrednosti (=prijem materijala za kongres, datum smeštaja, itd.) primaocu. Neposredni prenosi vrednosti a. Prenosi vrednosti se predstavljaju kao trošak za Merck, ne kao prihod primaoca. b. Ne-finansijski prenosi vrednosti se prikazuju na osnovu finansijske procene ne-finansijske potrošnje (roba/potrošeno vreme za uslugu, itd.). Posredni prenosi vrednosti a. Prenosi vrednosti koje ZO dobije od treće strane, npr. preko organizatora medicinskog događaja, se prijavljuju preko ZO kao primaoca. b. Prenosi vrednosti koje pojedinačni ZR dobije od treće strane, npr. preko organizatora medicinskog događaja, se prijavljuju preko pojedinačnog ZR kao primaoca. c. Prenosi vrednosti koje pojedinačni ZR dobije (npr. pozivi, pokrivanje putnih troškova ili troškova smeštaja) od ZO prijavljuju se kao naknade ka ZO. Prenosi vrednosti u slučaju delimičnog prisustva ili u slučaju otkazivanja a. U slučaju delimičnog prisustva, u slučaju otkazivanja, ili u slučaju da usluga ne bude isporučena, ali je prenos vrednosti ipak izvršen, npr. saglasno ugovornoj klauzuli, prenos vrednosti se objavljuje. b. Ukoliko nije došlo do isplate naknade, informacija o prenosu vrednosti nije deo objave.
6 Cross-border activities a. Cases of cross-border transfers of value to HCPs/HCOs, falling in the scope of the Transparency Code, are disclosed in accordance with the recipient s country of practice (HCP) or country of registration (HCO). b. If one HCP/HCO has several countries of practices / registration the country in which context the assignment took place discloses the transfers of value. Prekogranične aktivnosti a. Slučajevi prekograničnih prenosa vrednosti na ime ZR/ZO, koji ulaze u okvir Kodeksa o transparentnosti, objavljuju se saglasno sa mestom rada (ZR) ili zemljom u kojoj je registrovan (ZO). b. Ukoliko jedan ZR/ZO ima praksu u nekoliko zemalja ili je registrovan u nekoliko država, prenos vrednosti se objavljuje u državi koja je u kontekstu samog angažmana. Disclosure Type a. Disclosure of individual data: - If the signed consent declaration, with disclosure explicitly consented in a given validity period, is obtained the individual data and transfer of value in the reporting period are disclosed as required by the EFPIA disclosure template. - If in the closed contract, the disclosure consent has been explicitly granted by signature, and consent has not been denied (nonconsented) or withdrawn in at least one assignment by signature the individual data and transfer of value in the reporting period are disclosed as required by the EFPIA disclosure template. This is applied for countries with individual consent declaration required by local law or codices. Tip objave a. Objava pojedinačnih podataka: - Ukoliko se dobije potpisana izjava o saglasnosti, sa izričito datom saglasnošću za objavljivanje u datom periodu važenja, pojedinačni podaci i prenosi vrednosti u periodu izveštavanja se objavljuju saglasno obrascu za objavljivanje federacije EFPIA. - Ukoliko je u zaključenom ugovoru objavljivanje izričito odobreno potpisom ugovora, a saglasnost nije uskraćena ili povučena na bar jednom zadatku, pojedinačni podaci i transferi vrednosti u periodu izveštavanja se objavljuju saglasno obrascu za objavljivanje federacije EFPIA. Ovo se primenjuje u zemljama sa pojedinačnom izjavom o saglasnosti koju predviđa domaće zakonodavstvo. b. Disclosure of aggregated data: - Signed consent declarations with disclosure explicitly non-consented in the given validity period lead to disclosure of aggregated data of transfer of value in the reporting period as required by the EFPIA disclosure template. b. Objava zbirnih podataka: - Potpisana izjava o saglasnosti u kojoj izričito nema saglasnosti za objavljivanje, u datom periodu važenja, vodi do objavljivanja zbirnih podataka o prenosu vrednosti u periodu izveštavanja, saglasno obrascu za objavljivanje federacije EFPIA.
7 - Transfers of value to recipients from which consent declaration could not be obtained are disclosed on an aggregated basis. - If in any (at least one) contract closed, with transfer of value in the reporting period, the disclosure consent has explicitly not been granted by signature all transfers of value in the reporting period to the recipient are disclosed on an aggregated basis as required by the EFPIA disclosure template. This is applied for countries with individual consent declaration required by local law or codices. - Prenosi vrednosti primaocima od kojih se nije mogla dobiti saglasnost za objavljivanje se objavljuju kumulativno. - Ukoliko se u nekom (bar jednom) zaključenom ugovoru, sa naknadom u periodu izveštavanja, objavljivanje izričito ne odobrava potpisivanjem ugovora, svi prenosi vrednosti u periodu izveštavanja se objavljuju kumulativno saglasno obrascu za objavljivanje federacije EFPIA. Ovo se primenjuje u zemljama sa pojedinačnom izjavom o saglasnosti koju predviđa domaće zakonodavstvo. 4. Specific considerations Country unique identifier As guidance on the professional code in the EFPIA country, the unique identifiers include - the Full Name - for a HCP: the City of Principle Practice - for a HCO: the City where Registered - the Country of Principal Practice - the physical address of the Principal Practice, and - where applicable: the Unique Country Local Identifier (e.g. a professional code) Whether such full details can be publically disclosed depends on local applicable personal data protection laws and regulations Self-incorporated HCP A self-incorporate HCP constitutes a HCO (see above section Definition of HCO ) 4. Posebni faktori Jedinstvena identifikacija države Kao smernica za profesionalni kodeks u zemlji članici EFPIA, jedinstvenu identifikaciju obuhvataju - Puno ime i prezime - za ZR: Grad u kojoj je osnovna praksa za ZO: Grad u kojem je registrovana - Država osnovne prakse - poštanska adresa osnovne prakse, i - tamo gde je to primenjivo: Jedinstveni nacionalni identifikacioni broj (npr. kod zvanja) Da li se ovi detalji mogu objavljivati zavisi od nacionalnih zakona i propisa o zaštiti ličnih podataka. Samozaposleni ZR Samozaposleni ZR čini ZO (vidi gore Definicija ZO )
8 Multiannual agreements and transfers of value in different calendar years In case of multiannual agreements or other agreements based on which the transfers of value are provided in different calendar years, the information is included in the report about those which were effectively paid to the recipient in a given calendar year / reporting period. Methodology for R&D spend documentation Research and Development Transfers of Value will be disclosed in aggregate. In scope are ToV to HCPs/HCOs related to the planning and conduct of: a. Non-clinical studies (as defined in the OECD Principles of GLP) b. Clinical trials (as defined in Directive 2001/20/EC) c. Independent Investigator Trials and Investigator Sponsored Trials d. Non-interventional studies that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of, HCPs specifically for the study (cfr Section of the EFPIA HCP Code) Non-interventional studies that are retrospective in nature will be disclosed under the individual HCO spend category. The determination of R+D spend according to EFPIA regulations is based on Merck Healthcare s regular internal expense reporting and allocations derived from Clinical Operations Statistic. Višegodišnji sporazumi i prenosi vrednosti u različitim kalendarskim godinama U slučaju višegodišnjih sporazuma ili drugih sporazuma na osnovu kojih se vrše prenosi vrednosti u drugim kalendarskim godinama, informacija je uključena u izveštaj o onim prenosima vrednosti koje su izvršene primaocu u datoj kalendarskoj godini/periodu izveštavanja. Metodologija za dokumentaciju troškova u oblasti istraživanja i razvoja (R&D) Prenosi vrednosti za istraživanje i razvoj objavljuje se zbirno. U opsegu su prenosi vrednosti izvršeni ZR/ZO, a koji se odnose na planiranje i sprovođenje: a. nekliničkih ispitivanja (kako je to definisano u Principima dobre laboratorijske prakse OECD) b. kliničkih ispitivanja (kako je to definisano u Direktivi 2001/20/EC) c. Nezavisne istraživačke studije i klinička ispitivanja koje sponzoriše istraživač d. neintervencijskih studija koje su prospektivne prirode i koje uključuju prikupljanje podataka od pojedinačnih ZR ili u njihovo ime ili u ime grupa ZR, konkretno za datu studiju (član 15.1 Kodeksa o ZR) Neinterventna ispitivanja koja su po svojoj prirodi retrospektivna će biti objavljena pod kategorijom potrošnje za pojedinačnu ZO. Određivanje potrošnje na R+D prema propisima EFPIA zasnovano je na redovnom izveštavanju o internim troškovima i raspodelama Merck Healthcare koje proizilazi iz statističkih podataka kliničkog poslovanja.
9 5. Consent management 5. Upravljanje saglasnostima Consent collection Disclosure consent declaration is obtained for 5 years, starting 1 st of January of the calendar year of signing the declaration. Prikupljanje saglasnosti Saglasnost za objavljivanje se pribavlja na petogodišnji period, počevši od 1. januara kalendarske godine u kojoj je potpisana izjava. Management of recipient consent withdrawal a. If the consent to disclose individual data and transfer of value is withdrawn the individual data will be removed from the disclosed form within a period of 14 days after submitting written withdrawal. b. Consent may not be partially withdrawn or granted for selected assignments. Withdrawal of a disclosure consent for selected assignments leads to revocation of disclosing any individual data in the reporting period. Upravljanje povučenim saglasnostima primalaca a. Ukoliko primalac povuče saglasnost za objavljivanje pojedinačnih podataka i prenosa vrednosti, pojedinačni podaci će biti uklonjeni iz objavljenog obrasca u periodu od 14 dana od podnošenja pismenog povlačenja saglasnosti. b. Saglasnost se ne može delimično povući, niti se može selektivno dati za određene zadatke. Povlačenje saglasnosti za objavljivanje za određene zadatke vodi ka povlačenju objave svih pojedinačnih podataka u periodu izveštavanja. Management of recipient s request Requests and/or complaints by Recipients may be lodged with the local Merck Legal Entity and the Merck contact person named in the contract Partial consent No partial consent is granted. The Recipient only may give full consent to any aspect of disclosure or may decline consent in full. 6. Disclosure Form Upravljanje zahtevima primalaca Zahtevi i/ili pritužbe Primalaca mogu se podneti u lokalnom pravnom licu Merck i kontakt osobi u kompaniji Merck koja je naznačena u ugovoru. Delimična saglasnost Delimična saglasnost se ne daje. Primalac može samo da potpiše punu saglasnost za sve aspekte objavljivanja, ili može u potpunosti uskratiti svoju saglasnost. 6. Oblik objave Date of publication Disclosure will be made within six month after the end of the reporting period. The exact date of publication Datum objave Objava će biti izvršena u roku od šest meseci po završetku perioda izveštavanja. Tačni datum objave
10 varies between the EFPIA Countries and depends on legal stipulations. Disclosure platform Disclosure reports will be published on the Company s own website. Legal Stipulations in some countries require disclosure on an external central platform run by the government or a regulatory authority. In this case Merck will provide a link to the external source where the disclosure report is published. Disclosure language Reports will be disclosed in English and local language, using a bilingual disclosure template. 7. Disclosure of financial data and calculation rules Currency a. Total value of the transfers of value is disclosed in local currency (RSD) after conversion from foreign currencies per the exchange rates adopted on the day of documenting the effective payments in the electronic system. b. Reference point of conversion is EUR. c. Basis of the calculation of transfer rates is the company-internal exchange rate table which is updated monthly. d. Basis of the calculation of transfer rate for R&D costs is the official local exchange rate (RSD) of VAT included or excluded Transfers of value are disclosed with VAT included. varira u zemljama EFPIA i zavisi od zakona. Platforma objave Izveštaji će se objavljivati na internet stranici kompanije. Zakoni u nekim zemljama zahtevaju objavljivanje na eksternoj centralnoj platformi koju vodi vladino ili regulatorno telo. U tom će slučaju Merck ponuditi link do eksternog izvora na kojem je izveštaj objavljen. Jezik objave Izveštaji će se objavljivati na engleskom i na lokalnom jeziku, na dvojezičnom formularu objave. 7. Objavljivanje finansijskih podataka i pravila obračunavanja Valuta a. Ukupna vrednost prenosa vrednosti se objavljuje u domaćoj valuti (RSD) nakon konverzije sa strane valute, po važećem kursu na dan dokumentovanja uplate u elektronskom sistemu. b. Referentna tačka konverzije je EUR. c. Osnova obračuna kursa je interna tabela kursa koja se ažurira svakog meseca. d. Osnova obračuna kursa u vezi sa troškovima u oblasti istraživanja i razvoja je zvanični kurs u domaćoj valuti (RSD) na dan PDV Naknade se prikazuju sa uključenim PDV. Calculation rules a. Transfers of value effected in the reporting period are summed up (for individuals or aggregated) according Pravila obračunavanja a. Prenosi vrednosti izvršeni u periodu izveštavanja se sabiraju (za pojedince i zbirno) saglasno
11 to the segmentation of the EFPIA disclosure template requirements. b. Only amounts of payments effected within the given calendar year (= reporting period) are considered with the calculation (see also note re ToV date and ToV in different calendar years). c. Calculation is executed with amounts of harmonized (same) currency (see also note to Currency). segmentaciji iz obrasca za objavljivanje federacije EFPIA. b. U obračun ulaze isključivo iznosi plaćanja izvršenih u datoj kalendarskoj godini (=period izveštavanja) (vidi takođe i napomenu koja se odnosi na datum prenosa vrednosti i prenos vrednosti u različitim kalendarskim godinama). c. Obračun se vrši sa iznosima koji su u harmonizovanoj (istoj) valuti (vidi takođe i napomenu koja se odnosi na Valutu).
Methodological Note. - Merck Oy Finland -
Methodological Note 1. Introduction - Merck Oy Finland - This Methodological note summarizes the methodologies used in preparing Merck Oy s disclosure according to the EFPIA HCP/HCO Disclosure Code and
More informationEuropean Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements. Biogen Methodology Note
European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Biogen Methodology Note Contents Overview of the EFPIA Requirements... 3 Decisions...
More informationEuropean Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire
European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire Contents 1. Overview of the EFPIA Requirements... 3 2.
More informationEFPIA Disclosure Code 2016 Disclosures Shire Pharmaceuticals (including Baxalta US Inc.)
EFPIA Disclosure Code 2016 Disclosures Shire Pharmaceuticals (including Baxalta US Inc.) 1 Section 1: Reporting Approach for 2016 Data: On June 3rd, 2016, Shire acquired Baxalta. Due to the complexity
More informationEuropean Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements. Biogen Methodology Note
European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Biogen Methodology Note Contents Overview of the EFPIA Requirements... 3 Decisions...
More informationMedicines for Europe (MFE) HCP/HCO/PO Disclosure Transparency Requirements. Samsung Bioepis Methodology Note
Medicines for Europe (MFE) HCP/HCO/PO Disclosure Transparency Requirements Samsung Bioepis Methodology Note 1 Contents 1. Overview of the MFE Requirements 2. Decisions 3. Submission Requirements 4. Categories
More informationEFPIA HCP/HCO DISCLOSURE CODE
EFPIA HCP/HCO DISCLOSURE CODE EFPIA CODE ON DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS CONSOLIDATED VERSION 2014 Approved by
More informationMitsubishi Tanabe Pharma Group Methodology. Transfers of Value to Healthcare Professionals (HCP) and Healthcare Organisations (HCO) in Europe
Mitsubishi Tanabe Pharma Group Methodology Transfers of Value to Healthcare Professionals (HCP) and Healthcare Organisations (HCO) in Europe Introduction Under the EFPIA Code on Disclosure of Transfers
More informationThis document explains the methodology underlying Roche s EFPIA disclosure
This document explains the methodology underlying Roche s EFPIA disclosure It is common in many innovation-led industries for companies to engage independent experts or specialist organizations. Collaborations
More informationAgenda. EFPIA Disclosure Rules - Basics Latest Developments in Transcription As of 1/15/14
Agenda EFPIA Disclosure Rules - Basics Latest Developments in Transcription As of 1/15/14 1 EFPIA Released its Final Disclosure Code That Binds 33 Pharmaceutical Associations And 40 Pharmaceutical Companies
More informationNovartis Methodological Note
Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value
More informationTransfer of Value Disclosure Report as per National Legislation
Merz Pharmaceuticals GmbH Methodological Note Transfer of Value Disclosure Report as per National Legislation 1 I) Introductory note Merz supports laws and obligations which promote transparency around
More informationMethodology for Compliance with the ABPI Disclosure Code. Introduction Page 1. General Comments Page 2. Indirect Transfers of Value Page 3
Date Published: 15 th March 2017 Version: 20 (December 4, 2015) Index Methodology for Compliance with the ABPI Disclosure Code Introduction Page 1 General Comments Page 2 Indirect Transfers of Value Page
More informationAny healthcare professional and healthcare organization whose primary practice, principal professional address or place of incorporation
METHODOLOGICAL NOTE on the EFPIA disclosure of transfers of value to healthcare professionals and organizations Country: Russia Last Update: 25.04.2018 Version: 02; this document replaces previous drafts
More informationMethodology for Compliance with the Research-Based Pharmaceutical Industry (LIF) Disclosure Code
Methodology for Compliance with the Research-Based Pharmaceutical Industry (LIF) Disclosure Code Date Published: 31 May 2017 Index Annex 1: The disclosure in accordance with the Schedule 2 Template Annex
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More informationNovartis Methodological Note
Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More informationNovartis Methodological Note
Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value
More informationNovartis Methodological Note
Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value
More informationAny healthcare professional and healthcare organisation whose primary practice, principal professional address or place of incorporation
METHODOLOGICAL NOTE on the EFPIA disclosure of transfers of value to healthcare professionals and organisations Country: Finland Last Update: 25.04.2018 Version: 02; this document replaces previous drafts
More informationMedTech Europe Code of Ethical Business Practice. Disclosure Guidelines
MedTech Europe Code of Ethical Business Practice Disclosure Guidelines Final version: 13 September 2016 Table of Contents Preamble... 2 Chapter 1: Applicability of these Guidelines... 3 1. Scope... 3 2.
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More informationEFPIA Disclosure in Luxembourg Methodology Note - Boehringer Ingelheim
EFPIA Disclosure in Luxembourg Methodology Note - Boehringer Ingelheim 1. Introduction Collaborative working with HealthCare Professionals (HCP) and HealthCare Organizations (HCO) has long been a positive
More informationNovartis Methodological Note
Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value
More informationPfizer Hellas SA PRIMA/EFPIADisclosure Code Transparency Report
Pfizer Hellas SA PRIMA/EFPIADisclosure Code Transparency Report Methodological Note Malta 1. INTRODUCTION... 3 2. PFIZER ACTIVITIES PER EFPIA CATEGORY... 4 3. SOURCES OF INFORMATION... 6 4. DEFINITION
More informationNovartis Methodological Note
Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Predstavništvo AstraZeneca UK Limited 29004463 15 Bulevar Vojvode Misica, 11 000 Belgrade, Serbia
More informationNovartis Methodological Note
Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More informationDISCLOSURES OF TRANSFERS OF VALUE: SUMMARY OF METHODOLOGY
DISCLOSURES OF TRANSFERS OF VALUE: SUMMARY OF METHODOLOGY 1. ASTELLAS S COMMITMENT 1.1 Astellas is a member company of the European Federation of Pharmaceutical Industries and Associations ( EFPIA ). The
More informationNovartis Methodological Note
Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value
More informationCODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS
CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS Adopted November 2013, in force since 1 st of January 2014. INTRODUCTION The Association
More informationDOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2017 New Methodological Note
Document Title Methodological Note EFPIA Disclosure of Transfers of Value to Healthcare Professionals and Organisations ( Methodological Note on Disclosure ) Document Version 01 Effective Date 30JUN2017
More informationLEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements
LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP 2/14 Contents 1 Introduction... 3 2 Purpose... 3 3 Terminology and Definitions...
More informationAstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2015 Data in 2016
AstraZeneca AB 556011-7482 151 85 Södertälje Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2015 Data in 2016 Contents 1. Introduction... 4 Approach to disclosure
More informationMETHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: United Kingdom Year of Disclosure: 2017
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
AstraZeneca Latvija 40103252820 Skanstes iela 50, Rīga, LV-1013 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction... 4 Approach
More informationTitle: Methodological Note
Title: Methodological Note Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value Country:
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 ASTRAZENECA LUXEMBOURG SA N 2002 2220 862 AM BRILL 7B LU-3961 EHLANGE LUXEMBOURG Contents 1. Introduction...
More informationDisclosure Methodological Note For Aventis Pharma Ltd trading as Sanofi
Disclosure 2015 Methodological Note For Aventis Pharma Ltd trading as Sanofi INTRODUCTION The EFPIA Disclosure Code requires all EFPIA member companies to disclose transfers of value (TOV) such as support
More informationNovartis Pharma Austria Methodological Note
Novartis Pharma Austria Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of
More informationSanofi-Aventis Bulgaria EOOD Methodological Note
Sanofi-Aventis Bulgaria EOOD Methodological Note INTRODUCTION Collaboration between healthcare professionals and Pharmaceutical Companies has long been a positive driver for advancements in patient care
More informationMETHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: Austria Year of Disclosure: 2018 for 2017
More informationTitle: Methodological Note
Title: Methodological Note Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value Country:
More informationAbbVie Ltd 2015 ABPI Transparency Disclosure Methodological Notes
AbbVie Ltd 2015 ABPI Transparency Disclosure Methodological Notes As a member company of ABPI and EFPIA, AbbVie is committed to ensure that the nature and scope of our Transfers of Value (ToV) with healthcare
More informationLEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements
LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP 2/14 Contents 1 Introduction... 3 2 Purpose... 3 3 Terminology and Definitions...
More informationDOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2016 New Methodological Note
Document Title Methodological Note EFPIA Disclosure of Transfers of Value to Healthcare Professionals and Organisations in Poland ( Methodological Note on Disclosure ) Document Version 01 Effective Date
More informationMETHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: Ireland Year of Disclosure: 2018 for 2017
More informationMETHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: Belgium Year of Disclosure: 2017 for 2016
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Pharma Poland Sp. z o.o. 0000117902 Postepu 14, 02-676 Warsaw Contents 1. Introduction...
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
AstraZeneca Eesti OÜ Reg. kood 11733875 Järvevana tee 9 11314 Tallinn Estonia Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction...
More informationALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP
Methodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Hungarian Company representative Office ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Bulgaria EOOD Registration number 201340239 36 Dragan Tsankov, Bulgaria, Sofia1057 Contents
More informationAIFP CODE ON DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS
AIFP CODE ON DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS Approved by the AIFP General Meeting on 21 November 2013, last revision
More informationMethodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Romania Repressentative Office
Methodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Romania Repressentative Office ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca UK Limited Registered in England No 3674842 Registered Office, 2 Kingdom Street, London,
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Pharmaceuticals (Ireland) DAC, Company registration number: 55502 Ireland, Address of
More informationAstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
AstraZeneca AB 556011-7482 151 85 Södertälje Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction... 4 Approach to disclosure
More informationARPIM HCP/HCO DISCLOSURE CODE
ARPIM HCP/HCO DISCLOSURE CODE ARPIM CODE ON THE DISCLOSURE OF SPONSORSHIPS AND OTHER TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 LLC «AstraZeneca Ukraine» Legal address: Kyiv, Hvoiky str. 15/15,04080 Ukraine Actual address: Kyiv,
More informationEFPIA HCP/HCO DISCLOSURE CODE
EFPIA HCP/HCO DISCLOSURE CODE EFPIA CODE ON DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS CONSOLIDATED VERSION 2014 Approved by
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca SA 000638901000 4 Theotokopoulou & Astronafton 151 15 Maroussi, Athens, Greece PV: 2290014.1
More informationMethodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur
Methodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur Job Bag: SAGB.SA.18.03.0294 Date of Preparation: March 2018 INTRODUCTION The European
More informationMerz Pharma GmbH & Co. KGaA. Methodological Note. Transfer of Value Disclosure Report Belgium for the Calendar Year 2017
Merz Pharma GmbH & Co. KGaA Methodological Note Transfer of Value Disclosure Report Belgium for the Calendar Year 2017 1 I) Introductory note Merz supports laws and obligations which promote transparency
More informationEFPIA Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations
Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations ( HCP/HCO DISCLOSURE CODE) Frequently Asked Questions FAQ It is understood
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
NV ASTRAZENECA SA BE 0400.165.679 110, rue Egide Van Ophemstraat B-1180 Brussels Belgium Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents
More informationPfizer 2015 Disclosure Code Transparency Report
Pfizer 2015 Disclosure Code Transparency Report Methodological Note Pfizer Ireland 1. INTRODUCTION... 3 2. PFIZER ACTIVITIES PER EFPIA CATEGORY... 4 3. SOURCES OF INFORMATION... 6 4. DEFINITION OF THE
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Österreich GmbH Landstraßer Hauptstraße 1A, 1030 Wien Firmenbuch FN 51184x, HG Wien Contents
More informationBristol-Myers Squibb (BMS) Methodology Document in support of the EFPIA transparency disclosure code for HCP/HCO transfers of value pertaining to 2017
Bristol-Myers Squibb (BMS) Methodology Document in support of the EFPIA transparency disclosure code for HCP/HCO transfers of value pertaining to 2017 Publication date 30 June 2018 31TVAT31T...... Contents
More informationEFPIA Transparency / LIF public reporting of transfers of value. Sobi Methodology Note Transfers of Value (reported 2017) Sweden
EFPIA Transparency / LIF public reporting of transfers of value Sobi Methodology Note 2016 Transfers of Value (reported 2017) Sweden 1 1. Background A new disclosure code was approved by European Federation
More informationPharma Cooperation Code Transparency Report Methodological Note. Pfizer Switzerland
Pharma Cooperation Code Transparency Report 2017 Methodological Note Pfizer Switzerland 1. Table of Content 2. INTRODUCTION... 3 3. PFIZER ACTIVITIES PER EFPIA/SCIENCEINDUSTRIES CATEGORY... 4 4. DEFINITION
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More informationApproach to Employment Injury (EI) compensation benefits in the EU and OECD
Approach to (EI) compensation benefits in the EU and OECD The benefits of protection can be divided in three main groups. The cash benefits include disability pensions, survivor's pensions and other short-
More informationABPI Disclosure Methodological Note March 2017
ABPI Disclosure Methodological Note March 2017 This note describes the methods used by Roche in the UK to meet its obligations and the requirements for disclosing payments and Transfers of Value (ToV)
More informationOTSUKA PHARMACEUTICAL EUROPE LTD ( OTSUKA EUROPE ) EFPIA DISCLOSURE: AUSTRIA METHODOLOGY NOTE APPLICABLE TO TRANSFERS OF VALUE.
OTSUKA PHARMACEUTICAL EUROPE LTD ( OTSUKA EUROPE ) EFPIA DISCLOSURE: AUSTRIA METHODOLOGY NOTE APPLICABLE TO TRANSFERS OF VALUE FOR THE 2015 REPORTING YEAR Preamble This Methodology Note covers the disclosure
More informationPfizer 2017 Disclosure Code Transparency Report
Pfizer 2017 Disclosure Code Transparency Report Methodological Note Pfizer in Czech Republic 1. INTRODUCTION... 3 2. PFIZER ACTIVITIES PER EFPIA CATEGORY... 4 3. SOURCES OF INFORMATION... 5 4. DEFINITIONS...
More informationPfizer 2016 Disclosure Code Transparency Report
Pfizer 2016 Disclosure Code Transparency Report Methodological Note Pfizer Ireland 1. INTRODUCTION... 3 2. PFIZER ACTIVITIES PER EFPIA CATEGORY... 5 3. SOURCES OF INFORMATION... 7 4. DEFINITION OF THE
More informationSpain France. England Netherlands. Wales Ukraine. Republic of Ireland Czech Republic. Romania Albania. Serbia Israel. FYR Macedonia Latvia
Germany Belgium Portugal Spain France Switzerland Italy England Netherlands Iceland Poland Croatia Slovakia Russia Austria Wales Ukraine Sweden Bosnia-Herzegovina Republic of Ireland Czech Republic Turkey
More informationEFPIA DISCLOSURE METHODOLOGICAL NOTE JUNE 2016 MALTA IPSEN PRIMA TRANSPARENCY PROGRAM METHODOLOGICAL NOTE - MALTA
IPSEN PRIMA TRANSPARENCY PROGRAM METHODOLOGICAL NOTE - 2 Contents 1 PREAMBLE... 4 2 PURPOSE... 6 2.1 Terminology... 6 3 SCOPE OF THE DISCLOSURE... 7 3.1 Recipients... 7 3.1.1 HCP... 7 3.1.2 HCO... 8 3.1.3
More informationEIOPA Statistics - Accompanying note
EIOPA Statistics - Accompanying note Publication references: Published statistics: [Balance sheet], [Premiums, claims and expenses], [Own funds and SCR] Disclaimer: Data is drawn from the published statistics
More informationHow to complete a payment application form (NI)
How to complete a payment application form (NI) This form should be used for making a payment from a Northern Ireland Ulster Bank account. 1. Applicant Details If you are a signal number indemnity holder,
More informationEU-28 RECOVERED PAPER STATISTICS. Mr. Giampiero MAGNAGHI On behalf of EuRIC
EU-28 RECOVERED PAPER STATISTICS Mr. Giampiero MAGNAGHI On behalf of EuRIC CONTENTS EU-28 Paper and Board: Consumption and Production EU-28 Recovered Paper: Effective Consumption and Collection EU-28 -
More information11 th Economic Trends Survey of the Impact of Economic Downturn
11 th Economic Trends Survey 11 th Economic Trends Survey of the Impact of Economic Downturn 11 th Economic Trends Survey COUNTRY ANSWERS Austria 155 Belgium 133 Bulgaria 192 Croatia 185 Cyprus 1 Czech
More informationElectricity & Gas Prices in Ireland. Annex Business Electricity Prices per kwh 2 nd Semester (July December) 2016
Electricity & Gas Prices in Ireland Annex Business Electricity Prices per kwh 2 nd Semester (July December) 2016 ENERGY POLICY STATISTICAL SUPPORT UNIT 1 Electricity & Gas Prices in Ireland Annex Business
More informationDINARSKI OROČENI DEPOZITI / LOCAL CURRENCY DEPOSIT
DINARSKI OROČENI DEPOZITI / LOCAL CURRENCY DEPOSIT Vrsta depozita/type of Valuta depozita/currency of Kriterijumi za indeksiranje/ Criteria for index: Iznos sredstava koje Banka prima u depozit / The amount
More informationNOTE. for the Interparliamentary Meeting of the Committee on Budgets
NOTE for the Interparliamentary Meeting of the Committee on Budgets THE ROLE OF THE EU BUDGET TO SUPPORT MEMBER STATES IN ACHIEVING THEIR ECONOMIC OBJECTIVES AS AGREED WITHIN THE FRAMEWORK OF THE EUROPEAN
More informationLive Long and Prosper? Demographic Change and Europe s Pensions Crisis. Dr. Jochen Pimpertz Brussels, 10 November 2015
Live Long and Prosper? Demographic Change and Europe s Pensions Crisis Dr. Jochen Pimpertz Brussels, 10 November 2015 Old-age-dependency ratio, EU28 45,9 49,4 50,2 39,0 27,5 31,8 2013 2020 2030 2040 2050
More informationDISCLOSURE OF TRANSFERS OF VALUE TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS
DISCLOSURE OF TRANSFERS OF VALUE TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS METHODOLOGICAL NOTES Date of Issue: June 2017 Country Scope: Sweden, Poland, Norway & Denmark Version: 2.0 CONTENTS
More informationAny questions relating to this Methodology Note and / or the report should be directed to:
OTSUKA PHARMACEUTICAL (UK) LTD METHODOLOGY NOTE FOR THE 2016 REPORTING YEAR Preamble In order to comply with the requirements of the ABPI Code of Practice, Otsuka agrees to document and publish details
More informationEIOPA Statistics - Accompanying note
EIOPA Statistics - Accompanying note Publication reference: Published statistics: [Balance sheet], [Premiums, claims and expenses], [Own funds and SCR] Disclaimer: Data is drawn from the published statistics
More informationQuarterly Gross Domestic Product of Montenegro 3 rd quarter 2017
MONTENEGRO STATISTICAL OFFICE R E L E A S E No: 224 Podgorica, 22 December 2017 When using the data, please name the source Quarterly Gross Domestic Product of Montenegro 3 rd quarter 2017 The release
More informationBorderline cases for salary, social contribution and tax
Version Abstract 1 (5) 2015-04-21 Veronica Andersson Salary and labour cost statistics Borderline cases for salary, social contribution and tax (Workshop on Labour Cost Survey, Rome, Italy 5-6 May 2015)
More informationEU BUDGET AND NATIONAL BUDGETS
DIRECTORATE GENERAL FOR INTERNAL POLICIES POLICY DEPARTMENT ON BUDGETARY AFFAIRS EU BUDGET AND NATIONAL BUDGETS 1999-2009 October 2010 INDEX Foreward 3 Table 1. EU and National budgets 1999-2009; EU-27
More informationREPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
EUROPEAN COMMISSION Brussels,.4.29 COM(28) 86 final/ 2 ANNEXES to 3 ANNEX to the REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE
More informationRULES FOR THE REIMBURSEMENT OF TRAVEL AND SUBSISTENCE EXPENSES FOR EXCHANGE OF OFFICIALS
EUROPEAN COMMISSION CONSUMERS, HEALTH, AGRICULTURE AND FOOD EXECUTIVE AGENCY Consumers and Food Safety Unit RULES FOR THE REIMBURSEMENT OF TRAVEL AND SUBSISTENCE EXPENSES FOR EXCHANGE OF OFFICIALS CONSUMER
More informationDISCLOSURE OF TRANSFERS OF VALUE TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS IN THE UK
DISCLOSURE OF TRANSFERS OF VALUE TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS IN THE UK METHODOLOGICAL NOTES Date of Issue: March 30 th, 2017 Country Scope: United Kingdom Version: 1.1 CONTENTS
More informationInnovFin SME Guarantee
InnovFin SME Guarantee Implementation Update Reporting date: 30/09/2017 Disclaimer This presentation contains general information about the implementation results of InnovFin SME Guarantee, a facility
More information2017 Figures summary 1
Annual Press Conference on January 18 th 2018 EIB Group Results 2017 2017 Figures summary 1 European Investment Bank (EIB) financing EUR 69.88 billion signed European Investment Fund (EIF) financing EUR
More informationDPD CLASSIC (Slovenia) Slovenia 6,00 7,00 10,00 11,00 12,00 13,00 14,00 16,00 18,00 DPD CLASSIC - PARCEL DELIVERY TO THE EU
Parcel delivery in Slovenia DPD CLASSIC (Slovenia) Area up to up to up to up to 1 up to up to 2 up to 31. up to 40 kg up to 50 kg Slovenia 6,00 7,00 10,00 11,00 12,00 13,00 14,00 18,00 Prices are in EUR
More information